AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings
ABCL·Reported May 7, 2024·After market close
AbCellera Biologics Inc. reported Q1 2024 revenue of $10.0M, missed analyst consensus of $11.0M by $1.1M. Diluted EPS came in at $-0.14, beat the $-0.16 consensus by $0.02.
Revenue
$10.0Mmissed by $1.1M
Consensus: $11.0MDiluted EPS
$-0.14beat by $0.02
Consensus: $-0.16
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about AbCellera Biologics Inc.'s Q1 2024 earnings report.
AbCellera Biologics Inc. (ABCL) reported Q1 2024 earnings on May 7, 2024 after market close.
AbCellera Biologics Inc. reported revenue of $10.0M and diluted EPS of $-0.14 for Q1 2024.
Revenue missed the consensus estimate of $11.0M by $1.1M. EPS beat the consensus estimate of $-0.16 by $0.02.
You can read the 10-Q periodic report (0001628280-24-021159) directly on SEC EDGAR. The filing index links above go to sec.gov.